Case Studies

2025-06-20

AtaGenix Provides Custom CHALK10 and SD1 Protein Expression and Rabbit Polyclonal Antibody Services for Rice Chalkiness Research at China National Rice Research Institute

AtaGenix Laboratories Co., Ltd. partnered with the State Key Laboratory of Rice Biology and Breeding, China National Rice Research Institute, to provide custom protein expression and rabbit polyclonal antibody production services for a rice chalkiness study published in Plant Communications (DOI: 10.1016/j.xplc.2025.101354). The study identified CHALK10, an F-box protein, as a negative regulator of grain chalkiness by promoting the ubiquitination and degradation of SEMIDWARF-1 (SD1). AtaGenix expressed CHALK10 and SD1 proteins in Escherichia coli Rosetta (DE3) cells, purified them using affinity chromatography, and produced specific rabbit polyclonal antibodies. Validated through co-immunoprecipitation (co-IP) assays, these reagents supported the study’s findings on CHALK10’s role in regulating gibberellin-mediated starch metabolism, advancing rice grain quality research.

2025-06-20

Custom HSV-1 gB Protein Expression for Subunit Vaccine Research | AtaGenix

AtaGenix provided CHO-expressed HSV-1 glycoprotein B (gB) and its prefusion mutant gB H516P for a subunit vaccine study led by the Chinese Academy of Medical Sciences (Kunming). Both proteins were purified via Ni-NTA chromatography under identical conditions, ensuring matched quality for head-to-head immunogenicity comparison. Validated through ELISpot (IL-2, IFN-γ) and ELISA (gB-specific IgG), the proteins enabled the team to demonstrate that QS-21/CpG ODN-adjuvanted subunit vaccines induce robust cellular immune responses — published in Vaccine (2025, DOI: 10.1016/j.vaccine.2025.127241).

2025-06-20

Custom RMP & IKKβ Proteins Reveal a New Sepsis Therapeutic Target | AtaGenix

Naval Medical University needed matched sets of GST-tagged RMP variants and His-tagged IKKβ to map a novel protein-protein interaction in sepsis inflammation. AtaGenix delivered four E. coli-expressed proteins — including the critical S439A point mutant — enabling SPR, GST-pulldown, and ADP-Glo kinase assays that identified RMP as a negative regulator of NF-κB signaling. Published in Cell Communication and Signaling (2025, DOI: 10.1186/s12964-025-02278-w).

2025-06-20

Custom PRPF19 Protein Enables Ferroptosis Drug Target Discovery in Diabetic Nephropathy | AtaGenix

Researchers at Huazhong University of Science and Technology needed SPR-grade PRPF19 protein to prove that berberine directly binds this E3 ligase — the pivotal experiment for establishing PRPF19 as a druggable target in diabetic nephropathy. AtaGenix delivered high-purity PRPF19 (1.67 mg/mL) that enabled Biacore T200 confirmation of the berberine–PRPF19 interaction, supported by WB and IP validation. Published in Cell Communication and Signaling (2025, DOI: 10.1186/s12964-025-02253-5).

2025-06-20

AtaGenix Delivers Custom Rabbit Polyclonal Antibody Services for Haojie Hao’s Team at Wuhan Institute of Virology

AtaGenix Laboratories Co., Ltd. collaborated with the research team led by Haojie Hao at the Wuhan Institute of Virology to develop a custom mouse polyclonal antibody (pAb) against the Nipah virus (NiV) M protein, supporting a groundbreaking study published in Viruses (DOI: 10.3390/v17060831, IF: 3.8 Q2). The study revealed the critical role of N6-methyladenosine (m6A) modification in enhancing NiV replication and pathogenicity, particularly in the NiV-Malaysia strain. By designing specific antigens and delivering high-titer pAbs validated through Western blot assays in biosafety level 4 (BSL-4) conditions, AtaGenix enabled the team to confirm the M protein’s role in modulating host m6A machinery, advancing antiviral research.

2025-05-30

Custom PgUGT29 Protein & Antibody Enable Saponin Biosynthesis Discovery | AtaGenix

Researchers at Anhui University of Chinese Medicine needed functional recombinant PgUGT29/PgUGT72 proteins and a specific anti-PgUGT29 antibody to identify the enzyme responsible for PD-to-PD3 glycosylation in medicinal saponin biosynthesis. AtaGenix delivered E. coli-expressed, refolded proteins (>95% purity) and validated rabbit polyclonal antibodies. HPLC confirmed PgUGT29 as the C3-glucosyltransferase, while PgUGT72 (negative control) showed no activity. Published in Int J Mol Sci (2025, DOI: 10.3390/ijms26104832).

2025-05-30

Custom IgM-CH Protein & Anti-C5aR Antibody Power Fish Vaccine Adjuvant Discovery | AtaGenix

Researchers at Huazhong Agricultural University needed recombinant grass carp IgM-CH and anti-C5aR antibodies — two reagents that don't exist commercially — to validate complement C5a-CP as a fish vaccine adjuvant. AtaGenix delivered E. coli-expressed IgM-CH (>95% purity, refolded from inclusion bodies) and rabbit anti-C5aR pAbs (validated by flow cytometry and IF). The team demonstrated that C5a-CP enhances IgM+ B cell phagocytosis and achieves 96% relative survival against A. hydrophila and GCRV-II. Published in Fish and Shellfish Immunology (2025, DOI: 10.1016/j.fsi.2025.110415).

2024-11-05

Antibody Fragment Production

Using AtaGenix's mammalian cell expression system, various antibody fragments have been successfully expressed, including scFv, VHH, Fab, and scFv-Fc-scFv, meeting diverse research and development needs.The accompanying images demonstrate the expression results and workflow of antibody production using this advanced system.

2024-11-05

CHO Stable Cell Line: >3 g/L Antibody Titer & Viral Protein Production | AtaGenix

Two CHO stable cell line case studies from AtaGenix. Case 1: A therapeutic antibody program achieved >3 g/L fed-batch titer with sub-nanomolar affinity (KD = 7.36×10⁻¹¹ M), stable expression across passages, and full QC (SDS-PAGE purity, mycoplasma PCR, SPR kinetics). Case 2: A VZV gE viral glycoprotein stable line for vaccine antigen production, demonstrating AtaGenix's platform versatility across antibody and non-antibody targets.

2024-11-05

Large-Scale Recombinant Antibody Production

Using AtaGenix's proprietary XtenCHO™ mammalian expression system, full-length IgG, VHH, scFv, and Fab antibody fragments were successfully expressed. The accompanying SDS-PAGE analysis demonstrates the system's ability to produce high-quality proteins:

2024-11-05

Chimeric Antibody Expression and Validation | AtaGenix Custom Antibody Development Services

Chimeric antibody production combines the variable region of one species with the constant region of another to achieve optimal specificity and functionality. This approach ensures high binding affinity while maintaining robust stability and compatibility with downstream applications. Utilizing cutting-edge expression systems, production is scalable, cost-effective, and delivers high-purity antibodies suitable for therapeutic and research purposes.

2024-11-05

Bispecific Antibody Development

This case study showcases the quality and functionality assessment of Dubody bispecific antibodies through QC, SEC-HPLC monomer purity, and ELISA titer analysis. The results confirm high purity and robust activity, supporting their application in therapeutic development.